MI-EATON
11.6.2024 12:31:28 CEST | Business Wire | Press release
Intelligent power management company Eaton today announced its comprehensive suite of safety-focused electrified vehicle (EV) technologies will be on display June 18-20 in Hall 10-A36 at The Battery Show Europe in Stuttgart, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611322422/en/
Eaton plans to show its suite of safety-focused electrified vehicle (EV) technologies June 18-20 at The Battery Show Europe in Stuttgart, Germany. (Photo: Business Wire)
“While EV adoption continues to increase, we are helping our global customers meet the growing demand with innovative new technologies,” said Mark Schneider, president, Eaton’s eMobility business. “Safety is always a priority, whether the vehicle is powered by gasoline or electricity, and our EV solutions ensure occupants and the vehicle itself remain secure.”
Breaktor a pioneering high-voltage EV protection device
Eaton’s Breaktor® circuit protection technology combines the function of fuses, pyro switches, and contactors into a single coordinated and resettable device. As electric vehicle power levels increase, Breaktor solves the ever-increasing coordination challenge between fuses and contactors and offers extremely fast, safe and reliable protection for high-power battery and inverter systems.
3-in-1 battery vent valve improves battery pack leak testing
Eaton’s 3-in-1 battery vent valve is the first-to-market solution that is capable of three unique functions. In addition to passive and active venting, to provide overpressure relief for the vehicle’s battery pack, it includes an industry first battery-case leak-check mechanism.
It can open up during testing, allowing battery makers to completely leak-check the fully assembled battery pack with the valve in place. This provides customers with the peace of mind that all sealing surfaces of the battery pack are fully tested against water ingress. This Eaton-developed technology improves the safety of vehicles during normal operation and in the event of flooding situations.
The vent valve is precisely and flexibly designed to meet specific opening pressures and optimize venting. Its spring-based actuation technology allows Eaton to accommodate different opening pressure requirements with the same valve design to drive economies of scale.
Fuel tank isolation valve releases pressure in hybrid-electric vehicles
Eaton’s next-generation fuel tank isolation valve (FTIV) releases pressure in the gas tank of a hybrid-electric vehicle since the gas engine in a hybrid vehicle does not operate continuously. Pressure has to be released when the vehicle is in electric mode, and when refueling it’s important the tank is depressurized to avoid spit back.
High Power Lock Box terminals provide protection against the elements
Eaton’s High Power Lock Box (HPLB) terminals, which serve as the interface to a conductor and create a point where external circuits can be connected, are ideal for current and future EV solutions. They have numerous benefits over competitive solutions, including a space-saving profile, superior performance, cost savings, and reduced manufacturing complexity. They also provide efficiency, reliability and protection against the elements.
Eaton Bussmann series fuses optimized for high-powered electrified vehicles
Eaton Bussmann® series fuses feature ratings of up to 1,000 volts of direct current (VDC) and up to 600 amps, enabling them to meet the requirements for use in high-powered EVs.
Eaton's hybrid and EV fuses are designed to manage and protect the charging systems of electric commercial, passenger and high-performance vehicles such as sports cars and large sport-utility vehicles.
Learn more about Eaton’s EV solutions.
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace, and mobility markets. We are guided by our commitment to do business right, to operate sustainably, and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy sources, helping to solve the world’s most urgent power management challenges, and building a more sustainable society for people today and generations to come.
Eaton was founded in 1911 and has been listed on the New York Stock Exchange for more than a century. We reported revenues of $23.2 billion in 2023 and serve customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611322422/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom